Donna Reuter
Areas of Focus
Overview
Leveraging her experiences as a practitioner in the healthcare industry, Donna capably serves clients with her industry experience and her commitment to achieving client goals.
Career & Education
- Mitchell Hamline School of Law, J.D., 2019
- University of Minnesota, Pharm.D., 2011
- California State University, Fresno, B.A., Mass Communication and Journalism, 2006
- Minnesota
- District of Columbia
- U.S. District Court for the District of Minnesota
- U.S. Court of Appeals for the Eighth Circuit
Donna's Insights
Client Alert | 3 min read | 05.23.25
Executive Order Seeks Most-Favored-Nation Drug Pricing and HHS Announces Price Targets
On May 12, 2025, President Trump issued an Executive Order titled "Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients," which aims to reduce the costs of prescription drugs and biologics for American consumers and other payers. This Order revives a plan from President Trump’s first term and follows his April Executive Order, “Lowering Drug Prices by Once Again Putting Americans First,” which also sought to reduce drug prices. With drug prices in the United States nearly three times higher than many other countries, this second Order asks drug manufacturers to adopt Most-Favored-Nation (MFN) pricing for drugs sold in the United States or face potential regulation. MFN pricing would tether drug prices offered in the United States to the lower-cost prices offered in other comparably developed nations, such as Canada, Germany, or the United Kingdom.
Client Alert | 3 min read | 04.25.25
Firm News | 9 min read | 01.02.25
Crowell & Moring Elects 12 New Partners, Promotes Four to Senior Counsel and 25 to Counsel
Insights
- |
07.01.24
Crowell & Moring’s Health Law Blog
Practices
Donna's Insights
Client Alert | 3 min read | 05.23.25
Executive Order Seeks Most-Favored-Nation Drug Pricing and HHS Announces Price Targets
On May 12, 2025, President Trump issued an Executive Order titled "Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients," which aims to reduce the costs of prescription drugs and biologics for American consumers and other payers. This Order revives a plan from President Trump’s first term and follows his April Executive Order, “Lowering Drug Prices by Once Again Putting Americans First,” which also sought to reduce drug prices. With drug prices in the United States nearly three times higher than many other countries, this second Order asks drug manufacturers to adopt Most-Favored-Nation (MFN) pricing for drugs sold in the United States or face potential regulation. MFN pricing would tether drug prices offered in the United States to the lower-cost prices offered in other comparably developed nations, such as Canada, Germany, or the United Kingdom.
Client Alert | 3 min read | 04.25.25
Firm News | 9 min read | 01.02.25
Crowell & Moring Elects 12 New Partners, Promotes Four to Senior Counsel and 25 to Counsel
